

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A method of inducing an adaptive immune response in a patient to a target antigen comprising administering to said patient a flagellin protein[[,]] or [[a]] peptide fragment thereof[[,]] as claimed in Claim 12 in an amount effective to induce said response.
2. (currently amended) A method according to claim 1 wherein the flagellin protein or peptide fragment thereof is capable of directly inducing the dendritic cell adaptive immune response.
3. (previously presented) A method according to claim 1 wherein dendritic cell maturation is increased.
4. (currently amended) A method according to claim 1 wherein the flagellin protein or peptide fragment thereof is administered via a [[the]] mucosal route.
5. (currently amended) A method according to claim 1 wherein the flagellin protein or peptide fragment thereof is administered orally or intranasally.
6. (previously presented) A method according to claim 1 wherein the flagellin protein includes at least one of the conserved regions of the N terminal sequence and the C terminal sequence of flagellin.
7. (previously presented) A method according to claim 1 wherein the flagellin protein includes at least one of the conserved regions of residues 1-190 and 354-494 of *S. typhimurium* as shown underlined in Figure 8 herein.
8. (currently amended) A method as claimed in claim 1 wherein the flagellin protein or peptide fragment thereof and the target antigen are co-administered.

9. (currently amended) A method of manufacturing Use of a flagellin protein or peptide fragment thereof in the manufacture of a medicament for [[the]] induction of an adaptive immune response comprising combining a flagellin protein or peptide fragment thereof as claimed in Claim 12 with a pharmaceutically acceptable carrier, excipient or diluent in sterile pyrogen free form.

10. (currently amended) A method according to claim 9 wherein Use as claimed in Claim 9 characterised in that the medicament induces is for inducing recruitment of immature dendritic cells in mucosal vaccination such as to induce an adaptive immune response.

11. (currently amended) A method according to claim 9 wherein Use as claimed in Claim 9 characterised in that the medicament is an adjuvant.

12. (currently amended) A flagellin protein or peptide fragment thereof for use in therapy wherein characterised in that the flagellin protein or peptide fragment thereof is truncated, mutated or has deletions therein which allow it to retain its ability to induce the immune response.

13. (currently amended) A flagellin protein or peptide fragment thereof as claimed in Claim 12 which characterised in that it retains the ability to binds to intestinal or epithelial cell flagellin receptors and has retain immune signalling properties after the truncation, mutation or deletion.

14. (currently amended) A flagellin protein or peptide fragment thereof as claimed in Claim 12 wherein characterised in that the flagellin protein includes at least one of the conserved regions of residues 1-190 and 354-494 of *S. typhimurium* as shown underlined in Figure 8 herein.

15. (previously presented) An adjuvant composition comprising a flagellin protein or peptide fragment thereof as claimed in Claim 12 together with a pharmaceutically acceptable carrier, excipient or diluent in sterile pyrogen free form.

16. (original) A vaccine composition comprising an adjuvant composition as claimed in claim 15 and a target antigen.

17. (new) A flagellin protein or peptide fragment thereof as claimed in Claim 12 wherein the flagellin protein includes at least one of the conserved regions of the N terminal sequence and the C terminal sequence of flagellin.

18. (new) A method according to claim 9 wherein the medicament further comprises a target antigen.